Cheng AL - Search Results

1

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Cheng AL, et al. Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16. Lancet Oncol. 2009. PMID: 19095497 Clinical Trial.

2

Prognostic value of multidrug resistance 1, glutathione-S-transferase-pi and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy.

Hsu CH, Chen CL, Hong RL, Chen KL, Lin JF, Cheng AL. Hsu CH, et al. Among authors: cheng al. Oncology. 2002;62(4):305-12. doi: 10.1159/000065061. Oncology. 2002. PMID: 12138237

3

Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.

Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu CH, Tien HF, Chao TY, Chen LT, Whang-Peng J; Lymphoma Committee of Taiwan Cooperative Oncology Group. Cheng AL, et al. Hepatology. 2003 Jun;37(6):1320-8. doi: 10.1053/jhep.2003.50220. Hepatology. 2003. PMID: 12774010 Clinical Trial.

4

Low-dose thalidomide treatment for advanced hepatocellular carcinoma.

Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, Lee PH, Cheng AL. Hsu C, et al. Among authors: cheng al. Oncology. 2003;65(3):242-9. doi: 10.1159/000074477. Oncology. 2003. PMID: 14657598

5

Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.

Lu YS, Hsu C, Li CC, Kuo SH, Yeh KH, Yang CH, Hsu CH, Wu CY, Cheng AL. Lu YS, et al. Among authors: cheng al. Hepatogastroenterology. 2004 May-Jun;51(57):815-9. Hepatogastroenterology. 2004. PMID: 15143923 Clinical Trial.

6

Recent advances in non-surgical treatment for advanced hepatocellular carcinoma.

Hsu C, Cheng JC, Cheng AL. Hsu C, et al. Among authors: cheng al, cheng jc. J Formos Med Assoc. 2004 Jul;103(7):483-95. J Formos Med Assoc. 2004. PMID: 15318270 Review.

7

Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and Paclitaxel as first-line treatment.

Yang CH, Chen MC, Cheng AL, Hsu CH, Yeh KH, Yu YC, Whang-Peng J, Yang PC. Yang CH, et al. Among authors: cheng al. Oncology. 2005;68(4-6):350-5. doi: 10.1159/000086974. Epub 2005 Jul 11. Oncology. 2005. PMID: 16020962 Clinical Trial.

8

Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro.

Hsu CH, Gao M, Chen CL, Yeh PY, Cheng AL. Hsu CH, et al. Among authors: cheng al. Oncology. 2005;68(4-6):538-47. doi: 10.1159/000086998. Epub 2005 Jul 20. Oncology. 2005. PMID: 16037687

9

Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer.

Yeh KH, Lu YS, Hsu CH, Lin JF, Hsu C, Kuo SH, Li SJ, Cheng AL. Yeh KH, et al. Among authors: cheng al. Oncology. 2005;69(1):88-95. doi: 10.1159/000087304. Epub 2005 Aug 2. Oncology. 2005. PMID: 16088236 Clinical Trial.

10

Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients.

Su WP, Wen CC, Hsiung CA, Su IJ, Cheng AL, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu C, Hsu CH, Lu YS, Tien HF, Chao TY, Chen LT, Whang-Peng J, Chen PJ. Su WP, et al. Among authors: cheng al. World J Gastroenterol. 2005 Sep 14;11(34):5283-8. doi: 10.3748/wjg.v11.i34.5283. World J Gastroenterol. 2005. PMID: 16149133 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

803 results

Search Page